Tela Bio (TELA) Q3 2026 earnings review
Tela Bio cuts its operating loss, but revenue drops 8%
Tela Bio, a maker of surgical meshes for soft-tissue repair, cut its operating losses in half even as sales shrank again. Third-quarter revenue fell 8% from a year ago to $19 million because hospitals bought fewer plastic surgery meshes, though European and US hernia sales kept growing. New chief executive Heather Getz rolled out a plan to trim $17 million in yearly expenses, reducing quarterly cash burn to under $8 million.
| Revenue | $19.0M -8.4% from a year ago |
|---|---|
| Operating loss before one-offs (Adj. EBITDA) | -$3.4M cut by 55% from last quarter |
| Current debt due within a year | $56.3M reclassified from long-term debt |
| Annual cost reduction plan | $17.0M targets cash into 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because deep cost cuts reduced the cash burn while the debt covenant risk moved onto the current balance sheet. Cutting daily operating expenses by 23% from last quarter gives the business breathing room, so operations use far less cash. The caution: Tela Bio moved its entire $56 million loan into current debt due within a year, showing that the lender's revenue rules remain an urgent hurdle.
The question now is whether the expense cuts protect the sales force and satisfy the company's lender. Either the leaner team stabilizes revenue enough to secure a loan waiver, or the cuts shrink the field force just as new reps were maturing. The third-quarter 10-Q debt footnote and fourth-quarter revenue will settle both points.
🐂 Bull Case
Operating Expenses Fell 23% From Last Quarter
Tela Bio makes surgical meshes for hernia repair and plastic reconstruction. Because sales have shrunk this year, shrinking its operating deficit depends on cutting overhead rather than waiting for revenue. In the third quarter, operating expenses excluding restructuring charges fell 22.6% from the second quarter to $17.6 million, which is down 17.5% from a year ago.
- Sales and marketing: 68.6% of revenue, down 4.2 percentage points from a year ago and 16.6 points from last quarter
- General and administrative overhead: 15.8% of revenue, down 3.2 percentage points from a year ago
- Research and development: 8.5% of revenue, down 2.9 percentage points from a year ago
- Operating loss before interest, taxes, depreciation and one-offs (Adjusted EBITDA loss): $3.4 million, down 55% from last quarter
This matters because every dollar saved in daily spending directly reduces cash burn. Even after booking $2.0 million in severance and legal costs, the medical device maker cut its reported operating loss by 21% from the prior quarter to $7.3 million.
What to watch: fourth-quarter operating expenses excluding one-offs. Keeping spending near $17.6 million without a deeper drop in sales would show the cuts did not break the sales force.
International Sales and US Hernia Still Grow
While total revenue fell, the surgical mesh maker kept growing in Europe and in its core US hernia business. Chief executive Heather Getz said the company delivered "sequential revenue growth in the US hernia market and continued year-over-year growth in Europe". International sales rose 18% from a year ago, following 26% growth in the second quarter and 41% in the first.
Getz also noted that the business gained market share across its OviTex hernia portfolio, its reinforced tissue matrices for abdominal wall repair. That steady demand overseas and in hernia procedures cushions the drop in plastic surgery and gives the new leader a base to rebuild from.
What to watch: international revenue growth and US hernia unit volumes in the quarterly filing. Holding double-digit growth in Europe would help offset domestic reorganization disruption.
🐻 Bear Case
Entire $56.3M Term Loan Moves to Current Debt
Tela Bio owes $56.3 million under its credit facility with Perceptive Advisors, which matures in 2030 and requires the borrower to meet minimum revenue targets. In the press release, management highlighted that its cost cuts "extend cash runway into 2028".
The balance sheet tells a more urgent story. The device maker reclassified the entire $56.3 million loan from long-term debt to current debt due within twelve months, up from zero at year-end, while stockholders' equity fell to a deficit of $24.6 million. Under accounting rules, long-term debt moves to current liabilities when a covenant breach is probable or unwaived within a year.
Because the business holds only $22.9 million in total cash, it cannot repay an accelerated loan. That makes the 2028 cash projection dependent on lender relief, and a waiver could require new fees, higher interest, or dilutive stock issuances.
What to watch: the debt footnote in the third-quarter 10-Q filing. It will show whether Perceptive waived the revenue covenant and what terms the lender demanded in return.
Plastic Surgery Declines Pull Total Sales Down 8%
"My first quarter as CEO was focused on putting a plan in place to return TELA Bio to growth," chief executive Heather Getz said. Alongside hernia repair, the group sells OviTex PRS, a reinforced tissue product used in plastic and reconstructive surgery. Last quarter, executives had pointed to a second-half recovery for the plastic surgery line after stopping a dedicated sales rep pilot.
Instead, total revenue dropped 8.4% from a year ago and 1.7% from the second quarter to $19.0 million. Tela Bio said lower OviTex PRS unit volumes drove the decline, marking a second straight quarter of shrinking top-line sales as the business faces tough comparisons from late 2025.
What to watch: OviTex PRS revenue in the quarterly filing's segment table. Another double-digit drop would show that key plastic surgeons have not returned after the sales team reorganization.
Expired Inventory Write-Offs Cut Into Gross Margin
Because Tela Bio sells biological tissue products with a limited shelf life, slower sales leave unsold stock aging in warehouses. Reported gross margin fell 2.6 percentage points from a year ago to 64.9%, which the company attributed to a "higher charge for excess and obsolete inventory as a percentage of revenue".
Write-offs of expired product doubled from a year ago to $1.0 million, pushing total non-cash cost of revenue up 2.7 percentage points of sales to 5.6%. Excluding those write-offs and intangible amortization, gross margin was 71%, up 1 point from a year ago, while inventory on the balance sheet rose slightly to $11.6 million.
What to watch: expired product write-offs against the $11.6 million inventory balance in the fourth quarter. Continued $1 million quarterly write-offs would indicate that earlier manufacturing orders still exceed hospital demand.
Risks this quarter didn't answer
Three standing commercial concerns received no detailed figures in the third-quarter earnings release.
- Sales force headcount and ramp: Tela Bio booked $1.7 million in severance and cut sales spending by 21% from last quarter, leaving open how many of the newly hired territory managers remain.
- Hernia average selling prices: smaller robotic units have grown faster than revenue in prior quarters, and the release did not separate hernia unit growth from dollar growth.
- Hospital contracting and rival bundling: management gave no update on whether larger competitors' bundling practices are still blocking hospital access.
👓 Other Themes
New $17M Cost Cut Plan Targets 2028 Cash
Chief executive Heather Getz announced and implemented a restructuring program "to reduce annual operating expenses by $17.0 million and extend cash runway into 2028". Tela Bio recorded $1.7 million in severance and $0.3 million in legal expenses for the realignment during the third quarter. Management said the savings will let the business reallocate money toward returning to sales growth.
FDA Clears Liora Scaffold as Clinical Data Grows
Tela Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a new device for "soft tissue reinforcement". The group also added four peer-reviewed clinical publications and presentations showing favorable patient outcomes for its OviTex and OviTex PRS meshes compared to synthetic and biologic alternatives, while regaining compliance with Nasdaq's minimum share price rule.
💲 Other KPIs
Total cash fell by $7.8 million from the second quarter, down from $30.6 million at the end of June and $51.1 million at the end of 2025. The third-quarter cash burn slowed from $9.2 million in the second quarter and $11.3 million in the first quarter as operating expense cuts took hold.
Interest costs rose 74.8% from $1.2 million a year ago, holding near the $2.1 million recorded in both the first and second quarters of 2026. The higher expense comes from the $60 million Perceptive Advisors term loan closed in late 2025, which carries an interest rate above 12%.
Diluted share count increased 27.0% from 45.4 million a year ago, following the November 2025 stock and warrant offering. Because those losses are spread across more shares, GAAP net loss per share narrowed from $0.19 to $0.16 even though total GAAP net loss widened by 8.1% to $9.3 million.
🔮 Guidance
Unchanged. Tela Bio kept its qualitative plan for lower full-year operating expenses and sized the annual savings target at $17.0 million, while giving no revenue target after withdrawing its sales outlook last quarter. Nine-month operating expenses excluding severance and legal charges fell 5.9% from a year ago to $63.4 million.
❓ Key Questions
Did Perceptive waive the loan covenant after quarter-end?
Moving all $56.3 million of debt to current liabilities signals a probable or active covenant breach. Investors need to know the exact revenue thresholds and whether a waiver requires fees or equity.
How many sales reps were cut in the restructuring?
Sales and marketing spending fell by $3.4 million from the second quarter alongside $1.7 million in severance. Cutting territory managers who were hired in late 2025 could stall the planned return to revenue growth.
How much did OviTex PRS sales fall this quarter?
Management previously expected plastic surgery mesh volumes to recover in the second half of 2026, but PRS declines dragged total third-quarter revenue down 8%.
What are the launch plans for the Liora scaffold?
Tela Bio received FDA 510(k) clearance for the Liora Monofilament Scaffold this quarter, but the release gave no commercial launch timeline or target procedure market.